<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Basler L</dc:creator>
  <dc:creator>Kroeze SG</dc:creator>
  <dc:creator>Guckenberger M</dc:creator>
  <dc:date>2017</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Lung cancer is one of the leading causes of cancer death in men and women and treatment outcome continues to lag behind other common cancer types. A subset of lung adenocarcinoma patients exhibit a somatic mutation in EGFR or an ALK rearrangement. In these patients, targeted TKI therapy results in higher response rates, improved PFS and reduced side effects compared with platinum-based chemotherapy. Despite initial activity of the TKIs, ultimately all patients present with disease progression after about a year on TKI therapy due to resistance development. About 15-47% of patients present with limited oligoprogressive disease (OPD): such patients show only a limited number of metastases with progression in radiological imaging. Radical local treatment to all oligoprogressive lesions is thought to eradicate the de-differentiated clones and restore overall sensitivity of the metastatic disease. Retrospective studies suggest that aggressive local treatment using stereotactic body radiotherapy (SBRT), surgery or others can be used to eradicate TKI-resistant subpopulations enabling prolonged TKI treatment "beyond progression", which may lead to increased PFS and overall survival. This review focuses on the biological background of resistance development, systemic and local treatment options with a focus on SBRT, as well as challenges in defining the state of OPD and current clinical studies in oligoprogressive oncogene addicted NSCLC.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/259576</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.lungcan.2017.02.007</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28285694</dc:relation>
  <dc:source>Lung cancer (Amsterdam, Netherlands). - 2017</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">EGFR mutation</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Oligoprogressive disease (OPD)</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Oncogene addicted lung cancer</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Resistance to targeted therapy</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Stereotactic body radiotherapy (SBRT)</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Tyrosine kinase inhibitors</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Adenocarcinoma</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Adenocarcinoma of Lung</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Anaplastic Lymphoma Kinase</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Carcinoma, Non-Small-Cell Lung</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Disease Progression</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Drug Resistance, Neoplasm</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">ErbB Receptors</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Lung Neoplasms</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Mutation</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Neoplasm Staging</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Oncogene Addiction</dc:subject>
  <dc:subject xmlns:ns21="xml" ns21:lang="en">Protein Kinase Inhibitors</dc:subject>
  <dc:subject xmlns:ns22="xml" ns22:lang="en">Radiosurgery</dc:subject>
  <dc:subject xmlns:ns23="xml" ns23:lang="en">Receptor Protein-Tyrosine Kinases</dc:subject>
  <dc:subject xmlns:ns24="xml" ns24:lang="en">Retrospective Studies</dc:subject>
  <dc:subject xmlns:ns25="xml" ns25:lang="en">Survival Rate</dc:subject>
  <dc:subject xmlns:ns26="xml" ns26:lang="en">Treatment Outcome</dc:subject>
  <dc:subject xmlns:ns27="xml" ns27:lang="en">United States</dc:subject>
  <dc:title xmlns:ns28="xml" ns28:lang="en">SBRT for oligoprogressive oncogene addicted NSCLC.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
